Does DARATUMUMAB Cause Hepatitis b reactivation? 28 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 28 reports of Hepatitis b reactivation have been filed in association with DARATUMUMAB (DARZALEX). This represents 0.1% of all adverse event reports for DARATUMUMAB.
28
Reports of Hepatitis b reactivation with DARATUMUMAB
0.1%
of all DARATUMUMAB reports
11
Deaths
5
Hospitalizations
How Dangerous Is Hepatitis b reactivation From DARATUMUMAB?
Of the 28 reports, 11 (39.3%) resulted in death, 5 (17.9%) required hospitalization.
Is Hepatitis b reactivation Listed in the Official Label?
Yes, Hepatitis b reactivation is listed as a known adverse reaction in the official FDA drug label for DARATUMUMAB.
What Other Side Effects Does DARATUMUMAB Cause?
Plasma cell myeloma (2,980)
Infusion related reaction (2,557)
Off label use (2,494)
Pneumonia (1,450)
Neutropenia (1,351)
Drug ineffective (1,110)
Thrombocytopenia (1,089)
Death (1,088)
Pyrexia (1,032)
Dyspnoea (996)
What Other Drugs Cause Hepatitis b reactivation?
RITUXIMAB (914)
CYCLOPHOSPHAMIDE (801)
DOXORUBICIN (684)
VINCRISTINE (641)
PREDNISONE (583)
PREDNISOLONE (465)
LAMIVUDINE (308)
METHOTREXATE (305)
DEXAMETHASONE (293)
ETOPOSIDE (213)
Which DARATUMUMAB Alternatives Have Lower Hepatitis b reactivation Risk?
DARATUMUMAB vs DARATUMUMAB\HYALURONIDASE-FIHJ
DARATUMUMAB vs DARBEPOETIN ALFA
DARATUMUMAB vs DARIDOREXANT
DARATUMUMAB vs DARIFENACIN HYDROBROMIDE
DARATUMUMAB vs DAROLUTAMIDE